SU-E-T-551: Monitor Unit Optimization in Stereotactic Body Radiation Therapy for Stage I Lung Cancer

2015 ◽  
Vol 42 (6Part21) ◽  
pp. 3462-3462
Author(s):  
B-T Huang ◽  
J-Y Lu
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Stage I ◽  
Monitor Unit ◽  
Stereotactic Body Radiation ◽  
Stage I Lung Cancer

Stereotactic Body Radiation Therapy in Octogenarians With Stage I Lung Cancer

2014 ◽  
Vol 15 (2) ◽  
pp. 131-135 ◽  
Author(s):  
Ajay P. Sandhu ◽  
Steven K.M. Lau ◽  
Douglas Rahn ◽  
Sameer K. Nath ◽  
Daniel Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Stage I ◽  
Stereotactic Body Radiation ◽  
Stage I Lung Cancer

Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus

Lung Cancer ◽  
2009 ◽  
Vol 66 (1) ◽  
pp. 89-93 ◽  
Author(s):  
Si Yeol Song ◽  
Wonsik Choi ◽  
Seong Soo Shin ◽  
Sang-wook Lee ◽  
Seung Do Ahn ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Stereotactic Body Radiation Therapy ◽  
Stage I ◽  
Stereotactic Body Radiation ◽  
Stage I Lung Cancer

Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer

2006 ◽  
Vol 24 (30) ◽  
pp. 4833-4839 ◽  
Author(s):  
Robert Timmerman ◽  
Ronald McGarry ◽  
Constantin Yiannoutsos ◽  
Lech Papiez ◽  
Kathy Tudor ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Phase Ii ◽  
Local Control ◽  
Stereotactic Body Radiation Therapy ◽  
Early Stage ◽  
Stage I ◽  
Severe Toxicity ◽  
Stereotactic Body Radiation

PurposeSurgical resection is standard therapy in stage I non–small-cell lung cancer (NSCLC); however, many patients are inoperable due to comorbid diseases. Building on a previously reported phase I trial, we carried out a prospective phase II trial using stereotactic body radiation therapy (SBRT) in this population.Patients and MethodsEligible patients included clinically staged T1 or T2 (≤ 7 cm), N0, M0, biopsy-confirmed NSCLC. All patients had comorbid medical problems that precluded lobectomy. SBRT treatment dose was 60 to 66 Gy total in three fractions during 1 to 2 weeks.ResultsAll 70 patients enrolled completed therapy as planned and median follow-up was 17.5 months. The 3-month major response rate was 60%. Kaplan-Meier local control at 2 years was 95%. Altogether, 28 patients have died as a result of cancer (n = 5), treatment (n = 6), or comorbid illnesses (n = 17). Median overall survival was 32.6 months and 2-year overall survival was 54.7%. Grade 3 to 5 toxicity occurred in a total of 14 patients. Among patients experiencing toxicity, the median time to observation was 10.5 months. Patients treated for tumors in the peripheral lung had 2-year freedom from severe toxicity of 83% compared with only 54% for patients with central tumors.ConclusionHigh rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC. Both local recurrence and toxicity occur late after this treatment. This regimen should not be used for patients with tumors near the central airways due to excessive toxicity.

Sign in / Sign up

Export Citation Format

Share Document